Expansion of human regulatory T cells (Tregs) for clinical applications offers great promise for the treatment of undesirable immune responses in autoimmunity, transplantation, allergy, and antidrug antibody responses, including inhibitor responses in hemophilia A patients.

Foxp3⁺ regulatory T cells (Tregs) maintain self-tolerance and adoptive therapy, and using Foxp3⁺ Tregs has been proposed as treatment for autoimmune diseases.